Nasal spray medicine for treatment-resistant depression not recommended by NICE
More evidence on the clinical and cost effectiveness of esketamine needed
-
Digital and mobile interventions could support regular health services in helping people stop smoking and reduce their risk of obesity, says NICE
Health professionals can consider digital and mobile interventions as a supplement to regular services to support behaviour change in people at risk of developing chronic conditions.
-
NICE encourages further data collection on ‘game changing’ histology independent cancer drugs
Larotrectinib (also called Vitrakvi and made by Bayer), a new treatment for a range of cancers, can’t be recommended for use in the NHS because at its current price, it doesn’t have the potential to be cost-effective.
-
Make use of community pharmacists’ skills, says NICE
Community pharmacy teams have the potential to play a greater role in health promotion and prevention says NICE, in a new draft quality standard.
